<DOC>
	<DOCNO>NCT02121795</DOCNO>
	<brief_summary>This study evaluate efficacy switch emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) fix dose combination ( FDC ) emtricitabine/tenofovir alafenamide ( F/TAF ) FDC HIV-1 positive participant virologically suppress regimen contain FTC/TDF . This study consist 96 week double-blind treatment period . After Week 96 , participant continue blind study drug treatment attend visit every 12 week treatment assignment unblinded . All participant return unblinding visit give option receive open-label F/TAF attend visit every 12 week F/TAF commercially available , sponsor terminates F/TAF clinical development program .</brief_summary>
	<brief_title>Switch Study Evaluate F/TAF HIV-1 Positive Participants Who Are Virologically Suppressed Regimens Containing FTC/TDF</brief_title>
	<detailed_description />
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Key Ability understand sign write informed consent form , must obtain prior initiation study procedure Currently receive antiretroviral regimen contain FTC/TDF combination one third agent ≥ 6 consecutive month prior screen . Plasma HIV1 RNA level &lt; 50 copies/mL least 6 month precede screen visit ( measure least twice use assay ) experience two consecutive HIV1 RNA detectable level achieve confirm ( two consecutive ) HIV1 RNA detectable level current regimen past year . Plasma HIV1 RNA &lt; 50 copies/mL screen visit . Normal electrocardiogram ( ECG ) Estimated glomerular filtration rate ( eGFR ) ≥ 50 mL/min accord CockcroftGault formula creatinine clearance Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5 × upper limit normal range ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin ( individual document Gilbert 's syndrome Atazanavirassociated hyperbilirubinemia may total bilirubin 5 x ULN ) Adequate hematologic function Serum amylase ≤ 5 × ULN Females childbearing potential must agree utilize highly effective contraception method nonheterosexually active , practice abstinence screen throughout duration study treatment 30 day follow last dose study drug . Females stop menstruate ≥ 12 month documentation ovarian hormonal failure must serum follicle stimulate hormone ( FSH ) level screen within postmenopausal range base Central Laboratory reference range . Females utilize hormonal contraceptive one birth control method must use method least three month prior study dose . Males must agree utilize highly effective method contraception heterosexual intercourse nonheterosexually active , practice sexual abstinence first dose throughout study period 30 day follow last study drug dose . Key A new AIDSdefining condition diagnose within 30 day prior screen Hepatitis C virus ( HCV ) antibody positive HCV RNA detectable Individuals experience decompensated cirrhosis ( e.g. , ascites , encephalopathy , etc . ) Individuals receive ongoing treatment bisphosphonate treat bone disease ( eg , osteoporosis ) Females breastfeed Positive serum pregnancy test Have implant defibrillator pacemaker Current alcohol substance use judge investigator potentially interfere study compliance A history malignancy within past 5 year ( prior screen ) ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Day 1 Visit Individuals receive ongoing therapy medication use FTC , TAF , TDF antiretroviral third agent . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-1 Positive</keyword>
	<keyword>Virologically-suppressed</keyword>
</DOC>